HuGE Literature Finder
|
||
Records 1-52
|
Weight and the vitamin K expoxide reductase 1 genotype primarily contribute to the warfarin dosing in pediatric patients with Kawasaki disease.
Thrombosis research 2018 May 167 32-36. Wang Zhouping, Zhang Li, Huang Ping, Gu Xiaoqiong, Xie Xiaofei, Wang Yanfei, Li Wei, Zeng Qi |
|
Polymorphisms of vitamin K-related genes (EPHX1 and VKORC1L1) and stable warfarin doses.
Gene 2017 Oct . Chung Jee-Eun, Lee Kyung Eun, Chang Byung Chul, Gwak Hye S |
|
Influence of NR3C1 and VDR polymorphisms on stable warfarin dose in patients with mechanical cardiac valves.
International journal of cardiology 2017 Jun 236 393-397. Lee Kyung Eun, Chung Jee Eun, Yi Boram, Cho Yoon Jeong, Kim Hyun Jeong, Lee Gwan Yung, Kim Joo Hee, Chang Byung Chul, Gwak Hye S |
|
Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.
Clinical pharmacokinetics 2017 05 56 (5): 525-536. Green Bruce, Crauwels Herta, Kakuda Thomas N, Vanveggel Simon, Brochot An |
|
Evaluation of the pharmacokinetics of glibenclamide tablet given, off label, orally to children suffering from neonatal syndromic hyperglycemia.
European journal of clinical pharmacology 2016 Aug . Bouazza Naïm, Djerada Zoubir, Gozalo Claire, Busiah Kanetee, Beltrand Jacques, Berdugo Marianne, Urien Saik, Treluyer Jean-Marc, Polak Mich |
|
Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms.
The pharmacogenomics journal 2016 Aug . Kubo K, Ohara M, Tachikawa M, Cavallari L H, Lee M T M, Wen M S, Scordo M G, Nutescu E A, Perera M A, Miyajima A, Kaneko N, Pengo V, Padrini R, Chen Y T, Takahashi |
|
Association of genetic polymorphisms of CYP2C9 and VKORC1 with bleeding following warfarin: A case-control study.
Current clinical pharmacology 2016 Jan . Thatte Urmi |
|
[Population pharmacokinetic/pharmacodynamic modeling of warfarin by nonlinear mixed effects model].
Yao xue xue bao = Acta pharmaceutica Sinica 2015 Oct 50 (10): 1280-4. Lin Rong-fang, Lin Wei-wei, Wang Chang-lian, Huang Pin-fang, Fang Su-j |
|
Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex.
Omics : a journal of integrative biology 2015 May . Hatta Fazleen H M, Lundblad Mia, Ramsjo Margareta, Kang Ju-Hee, Roh Hyung-Keun, Bertilsson Leif, Eliasson Erik, Aklillu Ele |
|
CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy.
European journal of clinical pharmacology 2015 Apr 71 (4): 433-9. Chang Ming, Söderberg Mao Mao, Scordo Maria Gabriella, Tybring Gunnel, Dahl Marja-Lii |
|
Individualized phenytoin therapy for japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes.
Therapeutic drug monitoring 2015 Apr 37 (2): 229-35. Yamamoto Yoshiaki, Takahashi Yukitoshi, Imai Katsumi, Miyakawa Kou, Ikeda Hiroko, Ueda Yuki, Yamaguchi Tokito, Nasu Hirosato, Ohtani Hideyuki, Shigematsu Hideo, Kagawa Yoshiyuki, Inoue Yus |
|
Clinical Predictors Associated With Warfarin Sensitivity.
American journal of therapeutics 2015 Mar . Saleh Mohammad |
|
Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2015 Mar 26 (2): 167-74. Zhuang Wenfang, Wen Wei, Xuan Binbin, Chen Yanhong, Cao Yanan, Sun Zhixin, Ma J |
|
Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms.
Pharmacogenomics 2015 16 (3): 217-25. Nagai Rui, Ohara Minami, Cavallari Larisa H, Drozda Katarzyna, Patel Shitalben R, Nutescu Edith A, Perera Minoli A, Hernandez Wenndy, Kaneko Naoko, Hibiya Manabu, Takahashi Haru |
|
Warfarin dosage response related pharmacogenetics in Chinese population.
PloS one 2015 10 (1): e0116463. Li Siyue, Zou Yuangao, Wang Xia, Huang Xunbei, Sun Yong, Wang Yuqing, Dong Li, Jiang Ho |
|
CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: influence on quality of long-term anticoagulation.
Pharmacological reports : PR 2014 Apr 66 (2): 243-9. Nahar Risha, Saxena Renu, Deb Roumi, Parakh Rajiv, Shad Sujay, Sethi Prahlad K, Takkar Parul, Verma Ishwar |
|
[Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2014 Jan 35 (1): 13-7. Zhuang Wenfang, Wu Depei, Wang Zhaoy |
|
Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
European journal of clinical pharmacology 2014 Jan 70 (1): 47-56. Krishna Kumar Dhakchinamoorthi, Shewade Deepak Gopal, Loriot Marie-Anne, Beaune Philippe, Balachander Jayaraman, Sai Chandran B V, Adithan Chandrasekar |
|
Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.
Clinical pharmacokinetics 2013 Jul 52 (7): 567-81. Lu Yuan, Yang Jinbo, Zhang Haiyan, Yang J |
|
Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.
Clinical pharmacokinetics 2013 May 52 (5): 359-71. Abduljalil Khaled, Lazar Simone, Natanzon Michael, Wu Weidong, Zadoyan Gregor, Steffens Benedict, Kohl Victoria, Mörike Klaus, Tomalik-Scharte Dorota, Stingl Julia, Schwab Matthias, Harenberg Job, Gleiter Christoph, Fuhr U |
|
Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT.
Bone marrow transplantation 2012 Sep 47 (9): 1178-85. Balasubramanian P, Desire S, Panetta J C, Lakshmi K M, Mathews V, George B, Viswabandya A, Chandy M, Krishnamoorthy R, Srivastava |
|
White blood cells contribute to patient-specific warfarin dose for Han Chinese.
Chinese medical journal 2012 Jun 125 (11): 1960-3. Zhu Jin, Zheng Wen-Jie, Zhang Wei-Juan, Wang He-Yao, Wang Ch |
|
Multivariate analysis of the relation between diet and warfarin dose.
European journal of clinical pharmacology 2012 Mar 68 (3): 321-8. Rasmussen Morten Arendt, Skov Jane, Bladbjerg Else-Marie, Sidelmann Johannes J, Vamosi Marianne, Jespersen Jørg |
|
Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism.
Pharmacogenomics 2012 Feb 13 (3): 309-21. Zhang Wei, Zhang Wei-Juan, Zhu Jin, Kong Fan-Cui, Li Yan-Yan, Wang He-Yao, Yang Yuan-Hua, Wang Ch |
|
A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.
Clinical pharmacokinetics 2012 Jan 51 (1): 41-53. Verstuyft Céline, Delavenne Xavier, Rousseau Alexandra, Robert Annie, Tod Michel, Diquet Bertrand, Lebot Martine, Jaillon Patrice, Becquemont Laure |
|
Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
Clinical therapeutics 2011 Oct 33 (10): 1371-80. Cho Hyun-Jung, On Young-Keun, Bang Oh Young, Kim Jong-Won, Huh Wooseong, Ko Jae-Wook, Kim June Soo, Lee Soo-Yo |
|
Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.
European heart journal 2011 Aug 32 (15): 1909-17. van Schie Rianne M F, Wessels Judith A M, le Cessie Saskia, de Boer Anthonius, Schalekamp Tom, van der Meer Felix J M, Verhoef Talitha I, van Meegen Erik, Rosendaal Frits R, Maitland-van der Zee Anke-Hilse, |
|
Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients.
Drug metabolism and pharmacokinetics 2011 Jun 26 (3): 295-9. Kato Yuya, Ichida Fukiko, Saito Kazuyoshi, Watanabe Kazuhiro, Hirono Keiichi, Miyawaki Toshio, Yoshimura Naoki, Horiuchi Isao, Taguchi Masato, Hashimoto Yuki |
|
The Population Pharmacokinetics of R and S-Warfarin: Effect of Genetic and Clinical Factors.
British journal of clinical pharmacology 2011 Jun . Lane S, Al-Zubiedi S, Hatch E, Matthews I, Jorgensen AL, Deloukas P, Daly AK, Park BK, Aarons L, Ogungbenro K, Kamali F, Hughes D, Pirmohamed M |
|
Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients.
European journal of clinical pharmacology 2011 May . Shrif NE, Won HH, Lee ST, Park JH, Kim KK, Kim MJ, Kim S, Lee SY, Ki CS, Osman IM, Rhman EA, Ali IA, Idris MN, Kim JW |
|
Contribution of 1173C > T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation.
International journal of clinical pharmacology and therapeutics 2011 Jan 49 (1): 23-9. Yang J, Huang C, Shen Z, Miao |
|
Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients.
Journal of thrombosis and thrombolysis 2011 Jan 31 (1): 113-8. You Joyce H S, Wong Raymond S M, Waye Mary M Y, Mu Yawei, Lim Cadmon K, Choi Kai-Chow, Cheng Grego |
|
Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.
BMC medical genetics 2011 12 80. Suriapranata Ivet M, Tjong Wen Ye, Wang Tingliang, Utama Andi, Raharjo Sunu B, Yuniadi Yoga, Tai Susan |
|
Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily).
The American journal of cardiology 2010 Dec 106 (11): 1588-93. Hu Miao, Lee Michael H K, Mak Valiant W L, Tomlinson Bri |
|
VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China.
European journal of clinical pharmacology 2010 Dec 66 (12): 1217-27. Gu Qiang, Kong Yan, Schneede Jörn, Xiao Ying-Bin, Chen Lin, Zhong Qian-Jin, Wang Xue-Feng, Hao Jia, Chen Bai-Cheng, Chen Jing-J |
|
The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Clinical therapeutics 2010 Jun 32 (6): 1050-60. Namazi Soha, Azarpira Negar, Hendijani Fatemeh, Khorshid Maryam Banan, Vessal Ghazal, Mehdipour Ahmad Re |
|
Gender is an important determinant of the disposition of the loop diuretic torasemide.
Journal of clinical pharmacology 2010 Feb 50 (2): 160-8. Werner Ulrike, Werner Dierk, Heinbüchner Svetlana, Graf Bernhard, Ince Hüseyin, Kische Stefan, Thürmann Petra, König Jörg, Fromm Martin F, Zolk Oliv |
|
Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients.
Thrombosis research 2009 Jun 124 (2): 161-6. Yoshizawa Misa, Hayashi Hideki, Tashiro Yoshio, Sakawa Sonoko, Moriwaki Hideaki, Akimoto Takehide, Doi Osamu, Kimura Midori, Kawarasaki Yoshinori, Inoue Kazuyuki, Itoh Kunihi |
|
Genetic factors contribute to patient-specific warfarin dose for Han Chinese.
Clinica chimica acta; international journal of clinical chemistry 2008 Oct 396 (1-2): 76-9. Wang Ting-Liang, Li Hong-Lei, Tjong Wen-Ye, Chen Qian-Su, Wu Guan-Sheng, Zhu Hai-Tao, Hou Zi-Shan, Xu Shu, Ma Sheng-Jun, Wu Madeline, Tai Sus |
|
Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
European journal of clinical pharmacology 2007 Dec 63 (12): 1135-41. Miao Liyan, Yang Jian, Huang Chenrong, Shen Zhen |
|
Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
Pharmacogenomics 2007 Nov 8 (11): 1545-50. Borgiani Paola, Ciccacci Cinzia, Forte Vittorio, Romano Silvia, Federici Giorgio, Novelli Giusep |
|
Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes.
Clinical chemistry 2007 Jul 53 (7): 1199-205. Zhu Yusheng, Shennan Michael, Reynolds Kristen K, Johnson Nancy A, Herrnberger Matthew R, Valdes Roland, Linder Mark |
|
Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.
Therapeutic drug monitoring 2007 Feb 29 (1): 118-21. Goto Shuji, Seo Takayuki, Murata Tsukasa, Nakada Naoyuki, Ueda Nao, Ishitsu Takateru, Nakagawa Kazu |
|
Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not.
European journal of clinical pharmacology 2006 Sep 62 (9): 713-20. Meyer zu Schwabedissen Cordula, Mevissen Vera, Schmitz Fabian, Woodruff Seth, Langebartels Georg, Rau Thomas, Zerres Klaus, Hoffmann Rainer, Ortlepp Jan |
|
Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.
Clinical pharmacology and therapeutics 2005 Oct 78 (4): 362-9. Perini Jamila A, Vianna-Jorge Rosane, Brogliato Ariane R, Suarez-Kurtz Guilher |
|
Warfarin dose related to apolipoprotein E (APOE) genotype.
European journal of clinical pharmacology 2005 Jul 61 (5-6): 381-8. Kohnke Hugo, Sörlin Kristina, Granath Göran, Wadelius M |
|
Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.
Clinical pharmacology and therapeutics 2005 May 77 (5): 365-72. Loebstein Ronen, Vecsler Manuela, Kurnik Daniel, Austerweil Naomi, Gak Eva, Halkin Hillel, Almog Shlo |
|
Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.
The pharmacogenomics journal 2005 5 (3): 193-202. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A, Breskvar K, Dolzan |
|
[Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
Zhonghua yi xue za zhi 2004 Oct 84 (20): 1686-9. Huang Yue, Yang Jing-Fang, Qi Xiao-Lian, Wang Yu-Qin, Wang Wei-Zhi, Chen Bi |
|
Warfarin dosing and cytochrome P450 2C9 polymorphisms.
Thrombosis and haemostasis 2004 Jun 91 (6): 1123-8. Joffe Hylton V, Xu Ruliang, Johnson F Bradley, Longtine Janina, Kucher Nils, Goldhaber Samuel |
|
Pharmacogenetics of acenocoumarol pharmacodynamics.
Clinical pharmacology and therapeutics 2004 May 75 (5): 403-14. Morin Sandrine, Bodin Laurent, Loriot Marie-Anne, Thijssen Henk H W, Robert Annie, Strabach Soraya, Verstuyft Céline, Tregouet David-Alexandre, Dubert Liliane, Laurent-Puig Pierre, Funck-Brentano Christian, Jaillon Patrice, Beaune Philippe H, Becquemont Laure |
|
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
Clinical pharmacology and therapeutics 2004 Mar 75 (3): 204-12. Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H |
- Page last reviewed:Jul 30, 2019
- Page last updated:Aug 29, 2019
- Content source: